123 related articles for article (PubMed ID: 24625431)
1. Genomic analysis in active surveillance: predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2014 May; 24(3):303-10. PubMed ID: 24625431
[TBL] [Abstract][Full Text] [Related]
2. Predicting high-risk disease using tissue biomarkers.
Donovan MJ; Cordon-Cardo C
Curr Opin Urol; 2013 May; 23(3):245-51. PubMed ID: 23478499
[TBL] [Abstract][Full Text] [Related]
3. Predicting high risk disease using serum and DNA biomarkers.
Vesprini D; Liu S; Nam R
Curr Opin Urol; 2013 May; 23(3):252-60. PubMed ID: 23449497
[TBL] [Abstract][Full Text] [Related]
4. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance.
Trock BJ
Curr Opin Urol; 2014 May; 24(3):293-302. PubMed ID: 24710054
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
6. Sequencing the transcriptional network of androgen receptor in prostate cancer.
Chng KR; Cheung E
Cancer Lett; 2013 Nov; 340(2):254-60. PubMed ID: 23196061
[TBL] [Abstract][Full Text] [Related]
7. Tissue-based multigene expression tests for pretreatment prostate cancer risk assessment: current status and future perspectives.
Hiser WM; Sangiorgio V; Bollito E; Esnakula A; Feely M; Falzarano SM
Future Oncol; 2018 Dec; 14(29):3073-3083. PubMed ID: 30107751
[TBL] [Abstract][Full Text] [Related]
8. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
Auprich M; Bjartell A; Chun FK; de la Taille A; Freedland SJ; Haese A; Schalken J; Stenzl A; Tombal B; van der Poel H
Eur Urol; 2011 Nov; 60(5):1045-54. PubMed ID: 21871709
[TBL] [Abstract][Full Text] [Related]
9. How accurately can MRI detect indolent disease?
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2014 May; 24(3):264-9. PubMed ID: 24625426
[TBL] [Abstract][Full Text] [Related]
10. [New biomarkers to optimize the selection and follow up of patients with prostate cancer on active surveillance].
López-Guerrero JA; Casanova-Salas I; Fernández-Serra A; Rubio L; Calatrava A; García-Flores M; García-Casado Z; Rubio-Briones J
Arch Esp Urol; 2014 Jun; 67(5):462-72. PubMed ID: 24914846
[TBL] [Abstract][Full Text] [Related]
11. The prostate cancer genome: perspectives and potential.
Barbieri CE; Tomlins SA
Urol Oncol; 2014 Jan; 32(1):53.e15-22. PubMed ID: 24239470
[TBL] [Abstract][Full Text] [Related]
12. MRI and surveillance.
Ouzzane A; Puech P; Villers A
Curr Opin Urol; 2012 May; 22(3):231-6. PubMed ID: 22388665
[TBL] [Abstract][Full Text] [Related]
13. Genomic Predictors of Outcome in Prostate Cancer.
Boström PJ; Bjartell AS; Catto JW; Eggener SE; Lilja H; Loeb S; Schalken J; Schlomm T; Cooperberg MR
Eur Urol; 2015 Dec; 68(6):1033-44. PubMed ID: 25913390
[TBL] [Abstract][Full Text] [Related]
14. New tests for prostate cancer.
O'Hanlon LH
J Natl Cancer Inst; 2013 Nov; 105(22):1672-4. PubMed ID: 24198330
[No Abstract] [Full Text] [Related]
15. Unfavorable Pathology, Tissue Biomarkers and Genomic Tests With Clinical Implications in Prostate Cancer Management.
Nguyen JK; Magi-Galluzzi C
Adv Anat Pathol; 2018 Sep; 25(5):293-303. PubMed ID: 29727322
[TBL] [Abstract][Full Text] [Related]
16. [Markers for diagnosis, prediction and prognosis of prostate cancer].
Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854
[TBL] [Abstract][Full Text] [Related]
17. Understanding genomic alterations in cancer genomes using an integrative network approach.
Wang E
Cancer Lett; 2013 Nov; 340(2):261-9. PubMed ID: 23266571
[TBL] [Abstract][Full Text] [Related]
18. When is a genetic test suitable for prime time? Predicting the risk of prostate cancer as a case-example.
Li-Wan-Po A; Farndon P; Cooley C; Lithgow J
Public Health Genomics; 2010; 13(1):55-62. PubMed ID: 19439915
[TBL] [Abstract][Full Text] [Related]
19. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
Loeb S; Berglund A; Stattin P
J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
[TBL] [Abstract][Full Text] [Related]
20. Economic analysis of active surveillance for localized prostate cancer.
Kim S; Dall'Era MA; Evans CP
Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
